BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 21478036)

  • 1. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
    Terakawa T; Miyake H; Kusuda Y; Fujisawa M
    Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
    Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
    Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma.
    You D; Song SH; Cho YM; Lee JL; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
    World J Urol; 2015 Jan; 33(1):111-8. PubMed ID: 24710685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
    Minardi D; Lucarini G; Santoni M; Mazzucchelli R; Burattini L; Pistelli M; Bianconi M; Di Primio R; Scartozzi M; Montironi R; Cascinu S; Muzzonigro G
    Anticancer Res; 2013 Nov; 33(11):5017-22. PubMed ID: 24222145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma.
    Trávníček I; Branžovský J; Kalusová K; Hes O; Holubec L; Pele KB; Ürge T; Hora M
    Anticancer Res; 2015 Oct; 35(10):5661-6. PubMed ID: 26408740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma.
    Shim M; Song C; Park S; Choi SK; Cho YM; Kim CS; Ahn H
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2213-20. PubMed ID: 26215891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.
    Kwon WA; Cho IC; Yu A; Nam BH; Joung JY; Seo HK; Lee KH; Chung J
    Ann Surg Oncol; 2013 Dec; 20(13):4397-404. PubMed ID: 24081805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.
    Rautiola J; Lampinen A; Mirtti T; Ristimäki A; Joensuu H; Bono P; Saharinen P
    PLoS One; 2016; 11(4):e0153745. PubMed ID: 27100185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
    de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
    Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
    Méjean A; Ravaud A; Thezenas S; Colas S; Beauval JB; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Beisland C; Aitchison M; Oudard S; Patard JJ; Theodore C; Chevreau C; Laguerre B; Hubert J; Gross-Goupil M; Bernhard JC; Albiges L; Timsit MO; Lebret T; Escudier B
    N Engl J Med; 2018 Aug; 379(5):417-427. PubMed ID: 29860937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.
    Kawai Y; Osawa T; Kobayashi K; Inoue R; Yamamoto Y; Matsumoto H; Nagao K; Hara T; Sakano S; Nagamori S; Matsuyama H
    Asian Pac J Cancer Prev; 2015; 16(14):5687-90. PubMed ID: 26320436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy.
    Harada K; Miyake H; Kusuda Y; Fujisawa M
    BJU Int; 2012 Dec; 110(11 Pt C):E1131-7. PubMed ID: 22712620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?
    Bozkurt O; Hacıbekiroglu I; Kaplan MA; Duzkopru Y; Uysal M; Karaca H; Berk V; Inanc M; Duran AO; Ozaslan E; Ucar M; Ozkan M
    Clin Genitourin Cancer; 2015 Dec; 13(6):548-54. PubMed ID: 26320661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
    Nishikawa M; Miyake H; Harada K; Fujisawa M
    Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
    Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
    Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
    Ma X; Wang L; Li H; Zhang Y; Gao Y; Guo G; Liu K; Meng Q; Zhao C; Wang D; Song Z; Zhang X
    Sci Rep; 2016 Aug; 6():30886. PubMed ID: 27488093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.